Japan’s PMDA completes inspection of Lupin’s Mandideep facility (Unit-2)

Pharma major Lupin has announced the completion of the Good Manufacturing Practices (GMP) inspection of its Mandideep facility (Unit-2), by the Pharmaceutical and Medical Devices Agency (PMDA), Japan.

The inspection was conducted between May 14, 2019 and May 17, 2019. The PMDA inspection closed with no critical or major observations.

Lupin is the 8th largest generics pharmaceutical company by revenues. The Company is the 3rd largest pharmaceutical player in the US by prescriptions (IQVIA MAT Mar 2019); 3rd largest Indian pharmaceutical company by global revenues; 5th largest company in the Indian Pharmaceutical Market and 6th largest generic pharmaceutical player in Japan (IQVIA MAT Mar 2019).

For the financial year ended 31st March 2019, Lupin’s Consolidated sales and Net profits before exceptional items were at INR 163,694 million (USD 2.34 billion) and INR 9,466 million (USD 136 million) respectively.

Register as Visitor to CPhI China 2019 NOW!

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com.